This unique book brings together a wealth of data on the botanical, ethno-medicinal and pharmacological aspects of over 500 species of Asian medicinal orchids. It starts off by explaining the role and limitations of complimentary and herbal medicines, and how traditional Asian medicine differs from Western, “scientific” medicine. The different Asian medical traditions are described, as well as their modes of preparing herbal remedies. The core of the book presents individual medicinal orchid species arranged by genera. Each species is identified by its official botanical name, synonyms, and local names. Its distribution, habitat and flowering season, uses and pharmacology are described. An overview sums up the research findings on all species within each genus. Clinical observations are discussed whenever available, and possible therapeutic applications are highlighted. The book closes with chapters on the conservation of medicinal orchids and on the role of randomized clinical trials.
This sixth and final volume in the Genera Orchidacearum series treats 140 genera in tribes Dendrobieae and Vandeae of the largest subfamily, Epidendroideae, including some of the showiest orchids often used in hybridizing.
Fungi are eukaryotic microorganisms that are closely related to humans at cellular level. Human fungal pathogens belong to various classes of fungi, mainly zygo- cetes, ascomycetes, basidiomycetes, and deuteromycetes. In recent years, fungal infections have dramatically increased as a result of improved diagnosis, high frequency of catheterization, instrumentation, etc. However, the main cause remains the increasing number of immunosuppressed patients, mostly because of HIV infection and indiscriminate usage of antineoplastic and immunosuppressive agents, broad-spectrum antibiotics and prosthetic devices, and grafts in clinical settings. Presently available means of combating fungal infections are still weak and clumsy compared to control of bacterial infection. The present scenario of antifungal therapy is still based on two classes of antifungal drugs (polyenes and azoles). These drugs are effective in many cases, but display toxicity and limited spectrum of ef?cacy. The recent trend towards emergence of drug-resistant isolates in the clinic is an additional problem. In recent years, a few new antifungal drugs have entered the clinics, but they are expected to undergo same fate as the older antifungal drugs. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. However, it is too early to expect any novel drugs, as the antifungal drug discovery program is in the stage of infancy. Interestingly, several novel antifungal drug targets have been identi?ed and validated.
This work is a comprehensive information on the indigenous bioresources of North Eastern India with the scope of bioprospecting for discovery and commercialization of new sources and products and long-term ecological balance. The exploration, conservation and sustainable utilization of bioresources of world’s Megabiodiversity Hotspots are undeniable. North Eastern India is a recognised biodiversity hot spot where the evolutionary forces are at its optimum, making this region as centre of origin for many species. Although little bit exploratory studies have been conducted in this part of the globe but a scientific exploitation of the bioresources is almost lacking. Unscientific exploitation and overexploitation without proper knowledge of the bioresources may lead to imbalanced ecosystem of this mega diversity region. At the same time, very less exploration and exploitation will hamper biodiversity based development. Today, unscientific dramatic changes are underway in this region. Human activities are changing, degrading and destroying the bioresources in an unplanned manner. Scientific bioprospecting of the bioresources will boost the economy while ensuring conservation. This book offers comprehensive information about various levels of bioprospecting of the gene pool of this Indo-Burma Mega Biodiversity Hot Spot, the North East India, which is endowed with huge biodiversity potential for exploration and exploitation for the benefit of humankind. Also, this book highlights the less and merely explored part of the indigenous biodiversity of North East India with explanation towards their better sustainable exploitation for benefit of the people, economy and environment. The novelty of the book lies in expert coverage of the bioresources of this mega-diverse region including plants, microbes, insects etc. with provisions for their sustainable scientific utilization. This book portrays North East India as a melting pot of bioresources which are little explored and also those resources which are still to be explored. The book mainly highlights the bioprospecting approaches for North East Indian bioresources, and thus, it make itself a unique one in filling the knowledge gap that is there regarding the bioprospecting of the biodiversity of this special region on the earth. The book concludes by the ecotourism potential of this region. The target audiences for this book include biodiversity economists who are working on technology and bioresource management issues, and especially on biotechnology and biodiversity, development economists addressing the issues of bioresources in developing countries. These people may be in academia, in government, in non-governmental organizations and in private companies. The other target audiences group is policy scholars in government/public sectors who are interested in issues of biotechnology, IPRs, and biodiversity. In addition, scholars/experts in both development studies and resource management studies form another group of target audiences. Also, the book will be useful for the interaction between developed and developing nations regarding the issues of biodiversity and bioprospecting, as North Eastern India is the hub of Biodiversity.
"The aim of the Economic botany data collection standard is to provide a system whereby uses of plants in their cultural context can be described, using standardised descriptors and terms, and attached to taxonomic data sets. Studes on the uses of plants are becoming increasingly important and the standardisation of terms and a unified system to describe uses would be of enormous benefit to gatherers of information..."--Page 1.
This multi-compendium is a comprehensive, illustrated and scientifically up-to-date work covering more than a thousand species of edible medicinal and non-medicinal plants. This work will be of significant interest to scientists, researchers, medical practitioners, pharmacologists, ethnobotanists, horticulturists, food nutritionists, agriculturists, botanists, herbalogists, conservationists, teachers, lecturers, students and the general public. Topics covered include: taxonomy (botanical name and synonyms); common English and vernacular names; origin and distribution; agro-ecological requirements; edible plant part and uses; botany; nutritive and medicinal/pharmacological properties, medicinal uses and current research findings; non-edible uses; and selected/cited references. Each volume covers about a hundred species arranged according to families and species. Each volume has separate scientific and common names indices and separate scientific and medical glossaries.
This volume provides informative research on the scientific evidence of the health benefits that can be derived from medicinal plants and how their efficacies can be improved. It is divided into three sections that cover the phytochemistry of medicinal plants, disease management with medicinal plants, and novel research techniques in medicinal plants. The pharmacological benefits of several specific plants are discussed, addressing health issues such as metabolic and mental disorders, acute mountain sickness, polycystic ovarian syndrome, and specific diseases such as Huntington’s. It also looks at the role of antioxidants in disease management. Additionally, the book covers recent problems of drug resistance and how medicinal plants can serve as antibiotic, anthelmintic, and antiparasitic drugs that will be helpful for human and animals.
Documenting the latest research in the field of different pathogenic organisms, this book presents the current scenario about promising antimicrobials in the following areas: Part I. Plants as source of antibacterials, Part II. Naturally occurring antifungal natural products, Part III. Antiparasitic natural products, Part IV. Antiviral natural products. Renowned scientists from the globe have been selected as authors to contribute chapters. Use of plants for various ailments is as old as human civilization and continuous efforts are being made to improve medicinal plants or to product their bioactive secondary metabolites in high amounts through various technologies. About 200,000 natural products of plant origin are known and many more are being identified from higher plants and micro-organisms. Some plants based drugs are used since centuries and there is no alternative medicine for many such drugs as cardiac glycosides. Drug discovery from medicinal plants or marine micro-organisms continues to provide an important source of new drug leads. Research on new antibacterials represents a real and timely challenge of this century, particularly for the treatment of infections caused by clinical isolates that show multidrug resistance. The main microorganisms involved in the resistance process have been identified and given the acronym ESKAPE for Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacteriaceae. Multidrug resistant Mycobacterium tuberculosis including highly drug-resistant strains (XDR-TB) has also emerged as one of the most important clinical challenges of this century. Plants of diverse taxa and marine micro-organisms are rich source of these antimicrobials. An attempt has been made to compile the recent information about natural sources of antibacterials and their sustainable utilization. Increased panic of these pathogens warrants a growing demand for research to undertake the threat of multidrug resistance. The search for new antifungal, antiparasitic and antiviral natural products is far from devoid of interest. According to the WHO report in 2013, malaria still represents some 207 million cases worldwide and more than 3 billion of people are still exposed to this risk. Similarly, about 350 million people are considered at risk of contracting leishmaniasis. The fight against some viruses also requires that the research on natural products continue. For example, even if an antiretroviral with direct action was recently approved in Europe in 2013, its high cost does not allow to offer it to an exposed population in countries where the cost of drugs remains a problem for a large part of the population. These books are useful to researchers and students in microbiology, biotechnology, pharmacology, chemistry and biology as well as medical professionals.
